Exhibit 10.66

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

AMENDMENT NO. 1 TO THE COLLABORATION AGREEMENT

BETWEEN

EXELIXIS, INC., AND BRISTOL-MYERS SQUIBB COMPANY

THIS AMENDMENT NO. 1 (“Amendment No. 1”) to the Agreement (defined below) is
effective on December 17, 2008 (the “Amendment No. 1 Effective Date”) by and
between Exelixis, Inc., a Delaware corporation located at 170 Harbor Way, P.O.
Box 511, South San Francisco, California 94083-0511 (“Exelixis”) and
Bristol-Myers Squibb Company, a Delaware corporation headquartered at 345 Park
Avenue, New York, New York 10154 (“BMS”). Exelixis and BMS may be referred to
individually as a “Party” and collectively as the “Parties”.

WHEREAS, Exelixis and BMS entered into that certain Collaboration Agreement
executed as of December 11, 2008 (the “Agreement”) for the purposes of applying
Exelixis technology and expertise to the development and commercialization of
novel therapeutic and prophylactic products, including XL184 and XL281; and

WHEREAS, the Parties desire to amend the Agreement to amend the definition of
“Effective Date” and to clarify the treatment of possible regulatory filings as
set forth below.

NOW, THEREFORE, in consideration of the premises and mutual covenants herein
contained, and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Parties hereto agree as
follows:

AGREEMENT

 

1. AMENDMENT OF THE AGREEMENT

The Parties hereby agree to amend the terms of the Agreement as provided below,
effective as of the Amendment No. 1 Effective Date. To the extent that the
Agreement is explicitly amended by this Amendment No. 1, the terms of this
Amendment No. 1 will control where the terms of the Agreement are contrary to or
conflict with the following provision. Where the Agreement is not explicitly
amended, the terms of the Agreement will remain in full force and effect.
Capitalized terms used in this Amendment No. 1 that are not otherwise defined
herein shall have the same meanings as such terms have in the Agreement.

1.1 Amendment of Section 13.6. The Parties agree to delete Section 13.6 of the
Agreement in its entirety and replace it with the following:

“13.6 Effective Date; HSR Act Filing.

(a) Effective Date. The Parties agree that the effective date of this Agreement
is December 18, 2008 (the “Effective Date”).

 

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

--------------------------------------------------------------------------------

(b) Effect of HSR Act Filing on Rights & Obligations. If the exercise by BMS of
any of its rights under the Agreement, or the exercise by Exelixis of any of its
rights under the Agreement, requires the making of filings under the HSR Act, or
under any similar premerger notification provision in the European Union or any
other jurisdiction, then all rights and obligations directly related to the
exercise of such rights(s) (e.g., the corresponding license grants and
corresponding payment obligations) [ * ], and each Party agrees to diligently
make any such filings and respond to any request for information to expedite
review of such transaction. Each Party shall be responsible for its own costs in
connection with such filing, except that BMS shall be [ * ].

(c) Resolution of Regulatory Authority Opposition. If the antitrust enforcement
authorities in the U.S. make a second request under the HSR Act, or any
antitrust enforcement authority in another jurisdiction commences an
investigation into the exercise by BMS of any of its rights, then the Parties
shall, in good faith, cooperate with each other and take reasonable actions to
attempt to: (i) resolve all enforcement agency concerns about the transaction
under investigation; and (ii) diligently oppose any enforcement agency
opposition to such transaction. In the event the enforcement agency files a
formal action to oppose the transaction, the Parties shall confer in good faith
to determine the appropriate strategy for resolving the enforcement agency
opposition, including where appropriate, [ * ], with the [ * ]. Notwithstanding
the foregoing, nothing in this Section 12.6 shall [ * ].”

 

2. MISCELLANEOUS

2.1 Full Force and Effect. This Amendment No. 1 amends the terms of the
Agreement and is deemed incorporated into, and governed by all other terms of,
the Agreement. The provisions of the Agreement, as amended by this Amendment
No. 1, remain in full force and effect.

2.2 Further Actions. Each Party shall execute, acknowledge and deliver such
further instruments, and do all other acts, as may be necessary or appropriate
in order to carry out the purposes and intent of this Amendment No. 1.

2.3 Counterparts. This Amendment No. 1 may be signed in counterparts, each and
every one of which shall be deemed an original, notwithstanding variations in
format or file designation, which may result from the electronic transmission,
storage and printing of copies of this Amendment No. 1 from separate computers
or printers. Facsimile signatures shall be treated as original signatures.

Signature page follows

 

2

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.

--------------------------------------------------------------------------------

IN WITNESS WHEREOF, the Parties have caused this Amendment No. 1 to be executed
by their duly authorized representatives as of the Amendment No. 1 Effective
Date.

 

Bristol-Myers Squibb Company     Exelixis, Inc. Signature:   /s/ Jeremy Levin  
  Signature:   /s/ George Scangos Name:   Jeremy Levin     Name:   George
Scangos Title:   Senior Vice President     Title:   President & CEO Date:  
12/18/2008     Date:   12/17/2008

 

3

[ * ] = Certain confidential information contained in this document, marked by
brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.